Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
99 hedge funds and large institutions have $548M invested in Inhibrx, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 18 closing their positions.
146,350% more call options, than puts
Call options by funds: $2.93M | Put options by funds: $2K
43% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 28
2% less funds holding
Funds holding: 101 → 99 (-2)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
46% less capital invested
Capital invested by funds: $1.01B → $548M (-$466M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$26.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.8M |
| 4 |
PA
Perceptive Advisors
New York
|
+$11.2M |
| 5 |
Morgan Stanley
New York
|
+$5.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$35.3M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$25.9M |
| 3 |
TCM
Tybourne Capital Management
Hong Kong
|
-$5.96M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.75M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.71M |
INBX Hedge Fund Activity: Q1 2022 in Review
99 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q1 2022, worth a combined $548M — down 46% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of INBX and 16 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 40 added.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $26.6M. The largest seller was Wellington Management Group, cutting an estimated $35.3M.
- 99 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q1 2022, down from 101 in Q4 2021.
- Funds reported $548M of Inhibrx, Inc. Common Stock stock for Q1 2022, down 46% quarter-over-quarter.
- 16 funds opened new Inhibrx, Inc. Common Stock positions in Q1 2022 and 18 closed out, a net change of -2 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q1 2022 was Loomis, Sayles & Company, an estimated $26.6M added.
- The largest Inhibrx, Inc. Common Stock seller in Q1 2022 was Wellington Management Group, an estimated $35.3M sold.
Based on aggregated 13F filings for Q1 2022.